z-logo
Premium
Cutaneous S100‐negative, CD 1a‐positive histiocytosis successfully treated with combination therapy of oral methotrexate and corticosteroid
Author(s) -
Takahashi Chiaki,
Kaneta Kazuhiro,
Nomura Wakana,
Ohishi Yasushi,
Uehara Jiro,
Honma Masaru,
IshidaYamamoto Akemi,
Sato Hidetsugu,
Takagi Akiyoshi,
Iizuka Hajime
Publication year - 2015
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.12944
Subject(s) - birbeck granules , s100 protein , histiocyte , medicine , methotrexate , pathology , histiocytosis , dermatology , immunology , immunohistochemistry , antigen , langerhans cell , disease
S 100‐negative, CD 1a‐positive histiocytosis is a rare histiocytic disorder characterized by proliferation of histiocytic cells possessing a phenotype of epidermal Langerhans cells except for the lack of S 100 expression and Birbeck granules. We report the case of a Japanese man suffering from S 100‐negative, CD 1a‐positive histiocytosis. The patient showed numerous smooth erythematous 5–10‐mm papules/nodules on most of his body. The key histopathological feature was the presence of dermal infiltrates of non‐epidermotropic S 100‐negative CD 1a‐positive mononuclear cells. No systemic involvement was detected. Initially bath‐psoralen plus ultraviolet A therapy was effective, but the lesions became recalcitrant to this treatment. Methylprednisolone pulse therapy followed by low‐dose methotrexate (up to 30 mg/week) in combination with prednisolone (15 mg/day) effectively controlled the skin lesions.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom